A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors

False negative rate of COVID-19 PCR testing: a discordant testing analysis

(2021) Jamil N. Kanji et al.   Virology Journal

Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm

(2021) Alexandra Pum et al.   Biomolecules

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

(2021) Mario Mandala et al.   Journal for ImmunoTherapy of Cancer

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era

(2021) Chiara Burgaletto et al.   Cancers

Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors

(2021) David J. Lee et al.   Current Cardiology Reports

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure

(2020) Lauren M. Kucirka et al.   ANNALS OF INTERNAL MEDICINE

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

(2020) Meijuan Zheng et al.   Cellular & Molecular Immunology

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

(2020) Melissa Bersanelli   Immunotherapy

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

(2020) Marco Russano et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications

(2020) Steven Woloshin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease

(2020) Ritu Pasrija et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy

(2019) Yi-He Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors

(2018) Karthik Suresh et al.   Journal of Thoracic Oncology

Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

(2018) Jun Yeun Cho et al.   LUNG CANCER

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

(2017) Myriam Delaunay et al.   EUROPEAN RESPIRATORY JOURNAL

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy

(2017) Seth J. Rotz et al.   PEDIATRIC BLOOD & CANCER

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

(2016) M. Nishino et al.   CLINICAL CANCER RESEARCH

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology